ArticleData in brief2025
Dataset of pharmacotherapy in autism spectrum disorder.
Article in Data in brief, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacological interventions are widely used in autism spectrum disorder (ASD). We investigated the profile of psychopharmaceutical in a sample of children with ASD of low socioeconomic stratum enrolled and the public school in the city of Embu das Artes, Sao Paulo Brazil. From 149 children with a diagnosis of ASD identified in the municipal education department, informant consents were obtained from 129 children's parents. Data collection was performed through clinical evaluation of the children and face to face application of a questionnaire for parents regarding medication use. The participants socioeconomic stratum was mostly C (72.86 %), followed by B (16,27 %), D (10.07 %), and A (0.7 %) who do not undergo specialized multi-professional educational and behavioral intervention. Among the participants 57.36 % were under psychopharmacological intervention and 33.78 % were under a polypharmacy regimen. Typical antipsychotics were used for 35.4 % followed by atypical antipsychotics (27.43 %), antiseizure (19.47 %), and tricyclic antidepressants (7.08 %). The association of risperidone with valproic acid prevailed in 17.68 % of the sample. ASD levels 2 and 3, epilepsy and age were associated with a higher rate of psychopharmaceutical use. The present dataset can be used to investigate the rational use of medication in the ASD population to monitor potential adverse effects, and to compare with the ASD population across the world
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.